Note: Ingredients listed on restricted chemical lists
EC/CAS
2682-20-4
Name of the chemical
2-Methyl-2H-isothiazol-3-one
Concentration
N/A
EC/CAS
26172-55-4
Name of the chemical
5-chloro-2-methyl-4-thiazoline-3-ketone
Concentration
N/A
EC/CAS
55965-84-9
Name of the chemical
Mixture of 5-chloro-2-methyl-2H- isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6)
Concentration
N/A
EC/CAS
220-239-6
Name of the chemical
Mixture of 5-Chloro-2-methyl-isothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one 2-Methyl-2H-isothiazol-3-one
Concentration
N/A
EC/CAS
247-500-7
Name of the chemical
Mixture of 5-Chloro-2-methyl-isothiazol-3(2H)-one and 2-methylisothiazol-3(2H)-one
Concentration
N/A
General Information
Product name
BioPlex 2200 Syphilis IgG Control Set
Manufacturer Name
Bio-Rad Laboratories, Inc
Emergency telephone
(24h/365d) 1 800 039 008
Icons in SDS
Company Information
company name
Australia: Bio-Rad Laboratories Pty. Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
ro-sds@bio-rad.com, fds-msds.fr@bio-rad.com, sales.australia@bio-rad.com, sales.nz@bio-rad.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317, H412
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
HAZARDOUS COMPONENTS This test kit should be handled only by qualified personnel trained in laboratory procedures and familiar with their potential hazards. Specific warnings are given in the instructions for use. The absence of a specific warning should not be interpreted as an indication of safety. The following information is furnished for those product hazardous constituents that require regulatory control or disclosure at the concentration found in the product. Refer to Section 16 for the full text of any solely abbreviated or coded
Hazard statements
provided below and for the key / legend to abbreviations and acronyms Component
Contains
Positive Control - The positive controls are provided in a human serum matrix made from defribrinated plasma with added known BioPlex 2200 IgG analyte concentrations of Treponema pallidum 15-kDa IgG, 17-kDa IgG and 47-kDa IgG derived from Syphilis IgG human disease state plasma. 4 x 1.5 mL - Each human donor unit used to manufacture this product was tested by FDA accepted methods and found non- reactive for Hepatitis B Surface Antigen (HBsAg), antibody to hepatitis C (HCV) and antibody to HIV-1/HIV-2. - Preserved with 0.3% ProClin 300 ( 0.009% active ingredient), EC Index No 613-167-00-5 with CAS# 55965-84-9. GHS \ US HCS \ EC CLP Classification: WARNING; GHS07; H317, H412; P273, P280; WARNING P302 + P352, P333 + P313; P501. - Preserved with 0.1% sodium benzoate [C7H5O2Na], CAS# 532-32-1, EC No 208-534-8. Not subject to UN GHS, US HCS, EC CLP and analogous global GHS-based regulatory requirements in this product mixture and concentration. Negative Control - The negative controls are provided in a human serum matrix made from defibrinated plasma. Normal human BioPlex 2200 serum/plasma that is non-reactive for HBsAg and antibodies to HIV and HCV. Syphilis IgG - Preserved with 0.3% ProClin 300 ( 0.009% active ingredient), EC Index No 613-167-00-5 with 2 x 1.5 mL CAS# 55965-84-9. GHS \ US HCS \ EC CLP Classification: WARNING; GHS07; H317, H412; P273, P280; P302 + P352, P333 + P313; P501. - Preserved with 0.1% sodium benzoate [C7H5O2Na], CAS# 532-32-1, EC No 208-534-8. Not subject to UN GHS, US HCS, EC CLP and analogous global GHS-based regulatory requirements in this product mixture WARNING and concentration. Markings according to the United Nations (UN) Globally Harmonized System (GHS), United States Hazard Communication Standard (US HCS), European Commission (EC) 2008/1272/EC (EC CLP) guidelines and analogous GHS-based global regulations: This product has been conservatively classified and labeled in accordance with applicable United Nations (UN) GHS, United States Hazard Communication Standard (US HCS), related European Commission (EC) 2008/1272/EC (EC CLP) guidelines and applicable analogous GHS-based global regulations. The following regulated hazardous chemical concentrations are found in product component(s): SDSen663-1430 Revision D (February 2020) 2 of 14 0.3% ProClin 300 [ 0.009% active ingredients – reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one (C4H4ClNOS; CAS# 26172-55-4, EC No 247-500-7) and 2-methyl-2H -isothiazol-3-one (C4H5NOS; CAS# 2682-20-4, EC No 220- 239-6) (3:1)], EC Index No 613-167-00-5 with CAS# 55965-84-9. Comprehensive GHS Based Classification: Skin Sensitizer Category 1 Label(s): GHS07
Signal word
WARNING Label Hazard Statements: H317 May cause an allergic skin reaction. H412 Harmful to aquatic life with long lasting effects.
Precautionary statements
statements for product intended use and as codified on the product label) P273 Avoid release to the environment. P280 Wear protective gloves / protective clothing / eye protection / face protection. P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention. P501 Dispose of contents and container in accordance to local, regional, national, and international regulations.
Supplemental label elements
additional precautions to consider relative to specific customer use) P261 Avoid breathing mist / vapours / spray. P272 Contaminated work clothing should not be allowed out of the workplace. [Source: Raw Material vendor SDS, CCOHS databases and regulatory research] SDSen663-1430 Revision D (February 2020) 3 of 14